Clear Eyes Label Puts Naphazoline and Glycerin Back in Focus for Temporary Eye Relief
Clear Eyes Cooling Redness Relief pairs naphazoline hydrochloride with glycerin in a sterile ophthalmic solution designed for short-term relief of eye redness, dryness, and irritation. The updated DailyMed label describes a familiar over-the-counter strategy: constrict superficial conjunctival vessels to reduce visible redness while adding lubricant support to ease burning linked to dryness. The formulation sits at the intersection of cosmetic relief and symptom control, which makes the safety language as important as the active ingredients themselves.
The product contains glycerin 0.5% as the lubricant and naphazoline hydrochloride 0.03% as the redness reliever. Naphazoline is an alpha-adrenergic agonist, and its clinical effect depends on vasoconstriction of dilated ocular vessels. In practical terms, the drop can quickly make the eye look less red, but repeated or excessive use can also provoke the very rebound redness patients are trying to avoid. The label explicitly warns that overuse may produce increased redness of the eye, a familiar problem with topical vasoconstrictors in self-directed care.
The labeled uses are narrow and symptom-based: relief of redness due to minor eye irritations, temporary relief of burning and irritation due to dryness, and protection against further irritation or dryness. Those indications matter because they define where this product fits in real-world ophthalmic care. It is not positioned as a treatment for infectious conjunctivitis, corneal injury, glaucoma, or inflammatory eye disease. The product is a symptomatic bridge, not a disease-modifying therapy.
A narrow-angle glaucoma warning appears prominently on the label, and that warning carries direct bedside significance. Mydriasis or transient pupil enlargement can occur with topical sympathomimetic exposure, and patients with anatomically narrow angles face a different risk profile than someone using the drops for uncomplicated dryness or fatigue-related redness. The label also advises stopping use and seeking medical evaluation if eye pain, changes in vision, or persistent redness or irritation develop. Those are the symptoms that separate routine irritation from a potentially more serious ocular process.
A single sentence on the label carries an outsized amount of clinical weight: if the condition worsens or persists for more than 72 hours, the user should stop and ask a doctor. In an era of broad self-treatment, that 72-hour threshold is a useful safety valve. Persistent redness can signal dry eye disease severe enough to need formal assessment, allergic conjunctivitis, blepharitis, contact lens-related irritation, or corneal pathology. The label does not attempt to diagnose those conditions; it gives a clear cutoff for when self-care should end.
Dosing, Handling, and the Risk of Contamination
The dosing instructions are straightforward: instill 1 to 2 drops in the affected eye(s) up to four times daily. The simplicity of that instruction is part of the product’s appeal, but the label pairs it with standard sterility precautions. Users are told not to touch the tip of the container to any surface and to replace the cap after use. Those steps are not cosmetic details. Ophthalmic contamination can seed infection into a site where tissue is delicate and protective barriers are limited.
The product also instructs users to remove contact lenses before using the drops. Contact lens wear can worsen dryness and surface irritation, and preservatives such as benzalkonium chloride can interact poorly with lens use or ocular surface sensitivity. For patients who already have dry eye symptoms, the lens issue is often part of the problem, not just part of the solution. The label’s storage instructions are equally practical: store at 20°–25°C, or 68°–77°F.
Menthol appears among the inactive ingredients, which helps explain the “cooling” positioning of the product. The cooling sensation can be appealing to patients who associate it with freshness or rapid relief, but that sensory effect should not be mistaken for greater therapeutic depth. Relief is still governed by the pharmacology of vasoconstriction and lubrication, not by the subjective burn of menthol alone.
What the Ingredient Profile Says About OTC Eye Self-Care
This label reflects a common over-the-counter ophthalmic formula: one ingredient aimed at appearance and one aimed at comfort. Naphazoline hydrochloride addresses visible vascular congestion, while glycerin supports tear-film lubrication and surface comfort. The combination is clinically plausible because dryness and redness often travel together, especially after screen exposure, environmental irritants, or contact lens wear. A lubricating base can blunt the scratchy sensation that drives frequent rubbing, while the vasoconstrictor reduces the redness that prompts patients to keep escalating treatment on their own.
The limitation is built into the mechanism. Topical redness relievers can suppress the visible sign without changing the driver of the symptom. If the cause is chronic dry eye, allergy, or mechanical irritation, redness may return once the vasoconstrictor effect fades. Repeated use can then become a cycle: transient improvement, then rebound redness, then more frequent dosing. The label’s warning language is designed to interrupt that pattern before it becomes self-perpetuating.
The packaging details also place the product in the standard OTC monograph category, with marketing listed under OTC Monograph Drug and no DEA schedule. The label identifies Prestige Brands Holdings, Inc. as the packager and provides a 15 mL dropper bottle presentation. Those regulatory details do not change how the drops work, but they do anchor the product as a conventional, nonprescription ophthalmic option with established labeling rules rather than a novel formulation.
For clinicians, the label is a reminder that eye redness is not a diagnosis. A patient may use an OTC vasoconstrictor-lubricant blend for minor irritation, but pain, blurred vision, persistent symptoms, or worsening redness should push the encounter into formal eye evaluation. In daily practice, that line separates benign surface discomfort from conditions that need slit-lamp assessment, pressure evaluation, or a closer look at corneal integrity. The label draws that boundary clearly, and the clinical significance sits exactly there.